Ignite Creation Date:
2024-05-06 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 12:43 PM
Study NCT ID:
NCT03494504
Status:
COMPLETED
Last Update Posted:
2019-11-06
First Post:
2018-04-04
Brief Title:
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Sponsor:
Aldeyra Therapeutics Inc
Organization:
Aldeyra Therapeutics Inc
Study Overview
Official Title:
A Multi-Center Double-Masked Randomized Parallel-Group Vehicle-Controlled Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions 025 and 05 Compared to Vehicle in the Conjunctival Allergen Challenge Ora-CAC Model of Acute Allergic Conjunctivitis
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Multi-Center Double-Masked Randomized Parallel-Group Vehicle-Controlled Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None